MX380516B - Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico - Google Patents

Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico

Info

Publication number
MX380516B
MX380516B MX2018009944A MX2018009944A MX380516B MX 380516 B MX380516 B MX 380516B MX 2018009944 A MX2018009944 A MX 2018009944A MX 2018009944 A MX2018009944 A MX 2018009944A MX 380516 B MX380516 B MX 380516B
Authority
MX
Mexico
Prior art keywords
sub
sup
phenyl
dihydropyrimidin
pyrazin
Prior art date
Application number
MX2018009944A
Other languages
English (en)
Other versions
MX2018009944A (es
Inventor
Junli Chen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2018009944A publication Critical patent/MX2018009944A/es
Publication of MX380516B publication Critical patent/MX380516B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención, se refiere a un procedimiento para la sintetización de un compuesto de la fórmula (I), (ver fórmula) (I), R1 es fenilo, el cual se encuentra sustituido o insustituido con uno, dos o tres sustituyentes, independientemente seleccionados de entre halógeno y alquilo C1-6; R2, es alquilo C1-6; R3, es -CxH2x-; x, es 1, 2, 3, 4, 5, 6 ó 7; ó una sal o un diastereómero de éste, farmacéuticamente aceptable, el cual es de utilidad, para la profilaxis y el tratamiento de una enfermedad vírica, en un paciente, relativa a una infección por hepatitis B, o a una enfermedad causada por la infección por hepatitis B.
MX2018009944A 2016-02-19 2017-02-16 Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico MX380516B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016074132 2016-02-19
PCT/EP2017/053443 WO2017140750A1 (en) 2016-02-19 2017-02-16 Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid

Publications (2)

Publication Number Publication Date
MX2018009944A MX2018009944A (es) 2018-11-09
MX380516B true MX380516B (es) 2025-03-12

Family

ID=58054130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009944A MX380516B (es) 2016-02-19 2017-02-16 Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico

Country Status (15)

Country Link
US (1) US10927116B2 (es)
EP (2) EP3416966B1 (es)
JP (1) JP6672471B2 (es)
KR (2) KR102255228B1 (es)
CN (1) CN108718527B (es)
AR (1) AR107633A1 (es)
AU (2) AU2017219189B2 (es)
ES (1) ES2899369T3 (es)
HR (1) HRP20211816T1 (es)
IL (2) IL260153B (es)
MX (1) MX380516B (es)
PL (1) PL3416966T3 (es)
SG (2) SG10202110927VA (es)
SI (1) SI3416966T1 (es)
WO (1) WO2017140750A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3114128T3 (pl) * 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
KR102665544B1 (ko) 2017-06-26 2024-05-14 선샤인 레이크 파르마 컴퍼니 리미티드 디하이드로피리미딘 화합물 및 약제에서의 이의 용도
EP3645516A4 (en) 2017-06-27 2021-07-07 Janssen Pharmaceutica NV HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS
SG11202003320SA (en) * 2017-10-18 2020-05-28 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and uses thereof in medicine
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
TW202035412A (zh) * 2018-12-20 2020-10-01 比利時商健生藥品公司 雜芳基二氫嘧啶衍生物和治療b型肝炎感染之方法
CA3124317A1 (en) * 2018-12-20 2020-06-25 Janssen Pharmaceutica Nv Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
AU2020249331B2 (en) * 2019-03-25 2026-02-05 F. Hoffmann-La Roche Ag Solid forms of a compound of HBV core protein allosteric modifier
EP3980419A1 (en) 2019-06-06 2022-04-13 F. Hoffmann-La Roche AG Alternative process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
US20220241402A1 (en) 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
TW202122392A (zh) * 2019-07-31 2021-06-16 愛爾蘭商健生科學愛爾蘭無限公司 二氫嘧啶衍生物及其於治療hbv感染或hbv誘發的疾病之用途
CN112707910A (zh) * 2019-10-24 2021-04-27 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
CA3179165A1 (en) * 2020-04-28 2021-11-04 F. Hoffmann-La Roche Ag Process for the preparation of a chiral piperazine-2-carboxylic acid
WO2022220608A1 (ko) * 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10125131A1 (de) 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
CN100453542C (zh) 2007-04-30 2009-01-21 广东东阳光药业有限公司 2-杂环取代的二氢嘧啶消旋化合物的拆分方法
WO2010069147A1 (zh) 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用
MY182403A (en) 2012-08-24 2021-01-25 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PE20151951A1 (es) 2013-05-17 2015-12-26 Hoffmann La Roche Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
PL3114128T3 (pl) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B
WO2016016196A1 (en) * 2014-07-31 2016-02-04 F. Hoffmann-La Roche Ag Novel chiral resolution of 4-aryl-2-thiazol-2-yl-1,4-dihydropyrimidine-5-carboxylic acid esters
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues

Also Published As

Publication number Publication date
SG10202110927VA (en) 2021-11-29
AR107633A1 (es) 2018-05-16
EP3416966A1 (en) 2018-12-26
SG11201805595TA (en) 2018-07-30
JP6672471B2 (ja) 2020-03-25
IL260153B (en) 2021-10-31
CA3011650A1 (en) 2017-08-24
US10927116B2 (en) 2021-02-23
US20190010155A1 (en) 2019-01-10
AU2021203860A1 (en) 2021-07-08
AU2017219189A1 (en) 2018-06-28
BR112018016932A2 (pt) 2019-01-08
CN108718527A (zh) 2018-10-30
ES2899369T3 (es) 2022-03-11
KR102255228B1 (ko) 2021-05-25
MX2018009944A (es) 2018-11-09
EP3954691A1 (en) 2022-02-16
KR20210059801A (ko) 2021-05-25
IL286912A (en) 2021-10-31
SI3416966T1 (sl) 2022-01-31
AU2017219189B2 (en) 2021-04-01
HRP20211816T1 (hr) 2022-03-04
KR20180104177A (ko) 2018-09-19
EP3416966B1 (en) 2021-09-29
IL260153A (en) 2018-07-31
JP2019507144A (ja) 2019-03-14
PL3416966T3 (pl) 2022-01-17
WO2017140750A1 (en) 2017-08-24
CN108718527B (zh) 2022-06-28

Similar Documents

Publication Publication Date Title
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MX2021006902A (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
EA201391158A1 (ru) Диаминиевые соли фенотиазина и их применение
JP2016540742A5 (es)
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2020012827A (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes.
MX384745B (es) Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos.
PH12015501560A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
EA201890361A1 (ru) Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
MX2020013852A (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos.
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
EA201792087A1 (ru) ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP4248960A3 (en) Novel triterpene derivatives as hiv inhibitors
MX2021011614A (es) Formas solidas de un compuesto del modificador alosterico de la proteina del nucleo del vhb.
MX2021014850A (es) Procedimiento alternativo para la preparacion de acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il] metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5-a]pirazin-2-il]-c arboxilico.
MX2020011382A (es) Derivados de tetrahidropiranoxazina que tienen actividad inhibidora de beta-secretasa 1 (bace1) selectiva.
MA42972B1 (fr) Nouveaux composés sulfonimidoylpurinone et dérivés pour le traitement et la prophylaxie d'infection virale